Furthermore, the usefulness of adjuvant therapy using osimertinib for earlier pathological stage IA lung cancer with EGFR mutation is being verified in the ADAURA2 trial [11] The positioning of UFT in relation to osimertinib may become an issue with regard to the target stage of the ADAURA2 trial, too. The gene discussed is EGFR; the disease is lung carcinoma.